Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
Investing in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but breaking new ground can sometimes offer outsized rewards. On that note, Editas Medicine (NASDAQ: EDIT) and Intellia Therapeutics (NASDAQ: NTLA) are both exciting gene-editing businesses that aspire to treat or cure human illnesses using some of the most advanced biotechnologies that exist at the moment.
But there's a clear winner of this matchup when it comes to which is the more attractive opportunity to invest in. Let's dive in.
With its shares down by 87% in the last three years, Editas is definitely a battered biotech, but it isn't anywhere close to going out of business. Its only clinical-stage programs are a pair of gene therapies for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD), both of which are in early-stage trials, and both of which could be curative. It faces two main risks: Failing to prove that its therapies are safe and effective in its clinical trials, and failing to gain a market share if it eventually succeeds in getting its medicines approved.
Source Fool.com
Intellia Therapeutics Inc Stock
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Intellia Therapeutics Inc.
With a target price of 60 € there is potential for a 209.52% increase which would mean more than doubling the current price of 19.39 € for Intellia Therapeutics Inc.
